Gilead Sci­ences’ HIV treat­ment ar­se­nal is get­ting big­ger. The lead­ing drug­mak­er in the four-decade epi­dem­ic gained ...

FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across ...

Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.

Di­men­sion Cap­i­tal, an in­vest­ment firm fo­cused on the con­ver­gence of ma­chine learn­ing and life sci­ences, is rais­ing its third batch of cap­i­tal and seek­ing up to $750 mil­lion.

Amgen's Tezspire and Biokin's ADC post Phase 3 wins; Takeda exits China gene therapy deal; Gates Foundation backs ProFound on ...

Metriport raises $26M Series A led by Matrix to help doctors retrieve and prioritize patient data from across health systems.

Lonza names Celonic CEO Samanta Cimitan as first chief commercial officer; WuXi Bio, WuXi XDC post H1 revenue growth; ...

Is it the right call for Eli Lilly to stop disclosing its Phase 1 pipeline? Analysts and former Lilly execs weigh in.

Phar­ma has much to learn from the sur­pris­ing boom of tele­health sales of obe­si­ty drugs, No­vo Nordisk’s CEO Mike Doust­dar said at the End­points at #JPM26 event on the side­lines of the ...

Eli Lil­ly is get­ting more opaque as it gets big­ger. Ear­li­er this year, the drug­mak­er stopped dis­clos­ing its ear­ly-stage pipeline work. Its Phase 1 projects van­ished from the com­pa­ny’s ...

MassBio report shows MA biopharma jobs fell 3.1%, NIH awards dropped 6%, while China's drug pipeline grew 36% in 2025, ...

South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel ...